Estrogens, Conjugated

ORLANDO, Fla., Nov. 13, 2025 /PRNewswire/ -- Ingenus Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of Conjugated Estrogens Tablets, USP, the first FDA-approved generic equivalent to Premarin® Tablets. The product is available immediately to customers nationwide. Ingenus' Conjugated Estrogens Tablets, USP are available in all FDA-approved strengths: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg. "The availability of the first generic version of Premarin® Tablets represents a significant step forward in expanding access to this important therapy," said Paul Dutra, Executive Vice President at Ingenus Pharmaceuticals. "We are proud to continue our mission of delivering high-quality, affordable medicines to patients who need them." This launch marks a major milestone for Ingenus Pharmaceuticals in its growing women's health and complex generics portfolio. Indications Conjugated Estrogens Tablets is indicated in the treatment of moderate to severe vasomotor symptoms due to menopause and the prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. Important Safety Information There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women with daily oral conjugated estrogens (CE) 0.625mg alone relative to placebo. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women with daily oral CE 0.625mg combined with medroxyprogesterone acetate (MPA) 2.5mg relative to placebo. The WHI Memory Study (WHIMS) reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older, in both the estrogen alone and estrogen plus progestin arms. It is unknown whether these findings apply to younger postmenopausal women. The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer. In the absence of comparable data, these risks should be assumed to be similar for other doses of CE or CE and MPA, and other dosage forms of estrogens or combinations and dosage forms of estrogens and progestins. Estrogens with or without progestins should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Conjugated estrogens tablets should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or a history of these conditions; active arterial thromboembolic disease (e.g., stroke, myocardial infarction), or a history of these conditions; anaphylactic reaction or angioedema with Conjugated estrogens tablets; liver impairment or disease; thrombophilic disorders; pregnancy. Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. One large meta-analysis of prospective cohort studies reported increased risks that were dependent upon duration of use and could last up to >10 years after discontinuation of estrogen plus progestin therapy and estrogen-alone therapy. Extension of the WHI trials also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy. The WHI estrogen plus progestin sub-study reported a statistically non-significant increased risk of ovarian cancer. A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown. Estrogens increase the risk of gallbladder disease. Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy, because estrogens may be associated with increased thyroid binding globulin (TBG) levels. Most common adverse reactions (≥ 5 percent) are abdominal pain, asthenia, pain, back pain, headache, flatulence, nausea, depression, insomnia, breast pain, endometrial hyperplasia, leucorrhea, vaginal hemorrhage, and vaginitis. Please see full Prescribing Information of Conjugated Estrogens Tablets, USP, including Boxed Warning. About Ingenus Pharmaceuticals Ingenus Pharmaceuticals is a U.S. based generic pharmaceutical company committed to expanding access to high-quality, affordable medicines. The company focuses on complex generics across multiple therapeutic areas, delivering innovation that helps improve patient lives. For more information, visit ingenus.com Premarin® is a registered trademark of Pfizer Inc. Media Inquiries: Ingenus Pharmaceuticals, LLC – Media Relations Email: [email protected] Website: To report suspected adverse reactions, contact Ingenus Pharmaceuticals at [email protected] SOURCE Ingenus Pharmaceuticals LLC 21% more press release views with Request a Demo